DISCOVERY

  • Research type

    Research Study

  • Full title

    Assessment of the efficacy and safety of a new medical device in the local treatment of diabetic foot ulcers (DFUs): a prospective, randomized, controlled, double-blind, European, multicentre clinical trial.

  • IRAS ID

    220164

  • Contact name

    Michael Edmonds

  • Contact email

    michael.edmonds@kch.nhs.uk

  • Sponsor organisation

    URGO Research Innovation and Development

  • Clinicaltrials.gov Identifier

    NCT03110796

  • Clinicaltrials.gov Identifier

    BRC 2016-A01 154-47,

  • Duration of Study in the UK

    2 years, 3 months, 30 days

  • Research summary

    Metformin is currently widely used as an oral drug for the treatment of diabetes and is recognised for its capacity to make blood sugar levels return to normal. Scientific evidence suggests that Metformin, when applied topically may help promote healing of foot ulcers in patients with diabetes.

    Diabetic Foot Ulcers are a serious, yet common complication of diabetes mellitus, affecting approximately 15% of the world's diabetic population at least once in their lifetime. They are complex, chronic wounds which have a major long-term impact on the morbility, mortality and patient's quality of life. DFU's present a complex and costly therapeutic challenge and healing rates remain poor.

    An innovative wound healing dressing containing Metformin as an ancillary compound has been developed. The main objective of this study is therefore to measure the wound healing action of the wound healing dressing on diabetic foot ulcers. A computer system (IWRS) will randomly assign patients to either receive a neutral dressing containing no active substance, a dressing containing 3% active substance (dose 1) or a dressing containing 7% active substance (dose 2). When introduced into the medical device, the active substance Metformin HCl is designated as LU3103209.

    Clinical examination of the target diabetic foot ulcer as well as photographs, tracing and measurement of the wound surface area will be used to determine wound healing rate of the three devices at the end of treatment.

  • REC name

    West Midlands - South Birmingham Research Ethics Committee

  • REC reference

    17/WM/0194

  • Date of REC Opinion

    8 Jun 2017

  • REC opinion

    Further Information Favourable Opinion